News | May 17, 2024
Biocon posts Q4 FY24 PAT at Rs. 135 Cr
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
2024 full-year revenue guidance raised by US$ 2 billion
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
A game changing solution for the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
